Search Results

Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.

Viracta Therapeutics, Inc. announced that, in connection with the appointment of Michael Faerm as Viracta’s new Chief Financial Officer, Viracta’s Board of Directors granted Mr. Faerm a non-qualified stock option to purchase 500,000 shares of common stock under Viracta’s 2021 Inducement Equity Incentive Plan.

Viracta Therapeutics, Inc., a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately.

Viracta Therapeutics, Inc., a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, reported financial results for the first quarter of 2024 and provided a business update.

Viracta Therapeutics, Inc., a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced that Mark Rothera, President and Chief Executive Officer, and Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 11:00 a.m. EDT.

Viracta Therapeutics, Inc. today announced that topline results from Stage 1 of the NAVAL-1 trial of Nana-val.